Drugs / PA9159
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07345442 | Mar → Jun 2025 | allergic rhinitis | Anhui Palo Alto Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06916273 | Jul → Sep 2024 | asthma | Anhui Palo Alto Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05170763 | Nov 2021 → Jan 2022 | allergic rhinitis | Anhui Palo Alto Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07324707 | Oct 2025 → Mar 2026 overdue | asthma | Anhui Palo Alto Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07326995 | Feb 2025 → Feb 2026 overdue | asthma | Anhui Palo Alto Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05234580 | Apr → Oct 2022 | allergic rhinitis | Anhui Palo Alto Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PA9159 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05234580 ↗ |
| Modality | Small molecule | “PA9159 is a highly potent novel corticosteroid.” NCT05170763 ↗ |
| Route | Intranasal | “Single dose of PA9159 (5 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, one spray each in the left and right nostril.” NCT05170763 ↗ |